NVCT vs. NVO

Last updated Apr 2, 2026

Compare and contrast key facts about Nuvectis Pharma Inc (NVCT) and Novo Nordisk A/S (NVO).

Performance

NVCT vs. NVO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Nuvectis Pharma Inc (NVCT) and Novo Nordisk A/S (NVO). The values are adjusted to include any dividend payments, if applicable.

NVCT vs. NVO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
NVCT Nuvectis Pharma Inc	0.66%	39.56%	-35.13%	11.20%	130.77%
NVO Novo Nordisk A/S	-25.80%	-39.22%	-15.93%	54.84%	37.83%

Fundamentals

Market Cap NVCT : $165.78M NVO : $162.26B
EPS NVCT : -$1.31 NVO : $22.15
PB Ratio NVCT : 9.00 NVO : 0.84
Total Revenue (TTM) NVCT : $0.00 NVO : $297.20B
Gross Profit (TTM) NVCT : $0.00 NVO : $240.66B
EBITDA (TTM) NVCT : $0.00 NVO : $153.18B

Returns By Period

In the year-to-date period, NVCT achieves a 0.66% return, which is significantly higher than NVO's -25.80% return.

NVCT

• 1D: -1.68%
• 1M: -15.93%
• YTD: 0.66%
• 6M: 25.41%
• 1Y: -18.72%
• 3Y*: -16.62%
• 5Y*: —
• 10Y*: —

NVO

• 1D: -0.73%
• 1M: -0.01%
• YTD: -25.80%
• 6M: -36.19%
• 1Y: -43.88%
• 3Y*: -20.88%
• 5Y*: 3.69%
• 10Y*: 5.04%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

NVCT vs. NVO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NVCT

NVCT Risk / Return Rank: 27
NVCT Sharpe Ratio Rank: 26
NVCT Sortino Ratio Rank: 27
NVCT Omega Ratio Rank: 27
NVCT Calmar Ratio Rank: 26
NVCT Martin Ratio Rank: 29

NVO

NVO Risk / Return Rank: 10
NVO Sharpe Ratio Rank: 8
NVO Sortino Ratio Rank: 11
NVO Omega Ratio Rank: 10
NVO Calmar Ratio Rank: 11
NVO Martin Ratio Rank: 11

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NVCT vs. NVO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Nuvectis Pharma Inc (NVCT) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NVCT	NVO	Difference
Sharpe ratio Return per unit of total volatility	-0.31	-0.81	+0.51
Sortino ratio Return per unit of downside risk	-0.06	-0.99	+0.93
Omega ratio Gain probability vs. loss probability	0.99	0.86	+0.13
Calmar ratio Return relative to maximum drawdown	-0.46	-0.82	+0.36
Martin ratio Return relative to average drawdown	-0.71	-1.41	+0.71
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NVCT vs. NVO - Sharpe Ratio Comparison

The current NVCT Sharpe Ratio is -0.31, which is higher than the NVO Sharpe Ratio of -0.81. The chart below compares the historical Sharpe Ratios of NVCT and NVO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	NVCT	NVO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.31	-0.81	+0.51
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.10	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.16	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.21	0.46	-0.26

Correlation

The correlation between NVCT and NVO is 0.06, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

NVCT vs. NVO - Dividend Comparison

NVCT has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 4.94%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
NVCT Nuvectis Pharma Inc	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NVO Novo Nordisk A/S	4.94%	3.31%	1.68%	1.00%	1.20%	1.35%	1.87%	2.14%	1.45%	1.52%	2.87%	0.92%

Drawdowns

NVCT vs. NVO - Drawdown Comparison

The maximum NVCT drawdown since its inception was -77.89%, roughly equal to the maximum NVO drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for NVCT and NVO.

Drawdown Indicators

	NVCT	NVO	Difference
Max Drawdown Largest peak-to-trough decline	-77.89%	-74.70%	-3.19%
Max Drawdown (1Y) Largest decline over 1 year	-48.45%	-55.03%	+6.58%
Max Drawdown (5Y) Largest decline over 5 years	—	-74.70%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-74.70%	—
Current Drawdown Current decline from peak	-62.82%	-73.49%	+10.67%
Average Drawdown Average peak-to-trough decline	-53.25%	-17.56%	-35.69%
Ulcer Index Depth and duration of drawdowns from previous peaks	31.36%	31.83%	-0.47%

Volatility

NVCT vs. NVO - Volatility Comparison

Nuvectis Pharma Inc (NVCT) has a higher volatility of 13.22% compared to Novo Nordisk A/S (NVO) at 9.39%. This indicates that NVCT's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NVCT	NVO	Difference
Volatility (1M) Calculated over the trailing 1-month period	13.22%	9.39%	+3.83%
Volatility (6M) Calculated over the trailing 6-month period	36.65%	38.79%	-2.14%
Volatility (1Y) Calculated over the trailing 1-year period	61.61%	54.16%	+7.45%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	110.95%	37.82%	+73.13%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	110.95%	32.28%	+78.67%

Financials